Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Joseph Douglas Mancias

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0692-3717; OpenAlex author ID A5076287366; NIH RePORTER profile ID 6677742. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 3)
Trials
0
Grants
1
Labs led
1
Collaborators
144
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 5 papers · 2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers, 1 grant

Papers 29

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  4. KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer Last author DOI 10.64898/2026.10.01.756025↗
  5. Integrative genomic identification of therapeutic targets for pancreatic cancer. Co-author DOI 10.1016/j.celrep.2025.116191↗
  6. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. Last author DOI 10.1038/s41467-025-61242-x↗
  7. Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. Co-author DOI 10.1158/1078-0432.ccr-25-2333↗
  8. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  9. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label… Co-author DOI 10.1016/j.radonc.2023.110064↗
  10. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  11. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  12. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable… Co-author DOI 10.1016/j.ijrobp.2023.05.023↗
  13. Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer. Co-author DOI 10.1126/sciadv.adf9284↗
  14. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  15. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  16. NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Last author DOI 10.1158/2159-8290.cd-22-0043↗
  17. Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-0044↗
  18. Autophagy is required for proper cysteine homeostasis in pancreatic cancer through regulation of SLC7A11. Co-author DOI 10.1073/pnas.2021475118↗
  19. Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2020.10.016↗
  20. Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.108231↗
  21. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Co-author DOI 10.1038/s41586-020-2229-5↗
  22. Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0959↗
  23. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08087-z↗
  24. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Co-author DOI 10.1038/s41588-019-0475-y↗
  25. What Patients Look for When Browsing Online for Pancreatic Cancer: The Bait Behind the Byte. Co-author DOI 10.1007/s00268-018-4719-2↗
  26. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Co-author DOI 10.1002/cncr.30856↗
  27. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2016.70.2134↗
  28. Assessing the Accuracy and Readability of Online Health Information for Patients With Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2016.0730↗
  29. KRAS: feeding pancreatic cancer proliferation. First author DOI 10.1016/j.tibs.2013.12.004↗

Grants 1

  1. Targeting iron metabolism in pancreatic adenocarcinoma to overcome KRAS inhibitor therapeutic resistance R01CA301542↗

Closest collaborators

The 25 strongest of 144 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew J. Aguirre · 10 shared papers, 2022–2026 · strength 1.59
  2. Brian Matthew Wolpin · 9 shared papers, 2017–2026 · strength 1.31
  3. Jonathan Andrew Nowak · 7 shared papers, 2022–2026 · strength 1.04
  4. Thomas E. Clancy · 7 shared papers, 2017–2026 · strength 0.97
  5. Harshabad Singh · 6 shared papers, 2022–2026 · strength 0.95
  6. James M. Cleary · 6 shared papers, 2022–2026 · strength 0.94
  7. Alec C. Kimmelman · 8 shared papers, 2014–2023 · strength 0.86
  8. Stephanie K. Dougan · 5 shared papers, 2022–2026 · strength 0.85
  9. Kimberly J. Perez · 6 shared papers, 2017–2026 · strength 0.84
  10. Douglas Adam Rubinson · 5 shared papers, 2022–2026 · strength 0.75
  11. João A. Paulo · 5 shared papers, 2019–2026 · strength 0.58
  12. Brandon M. Huffman · 3 shared papers, 2025–2026 · strength 0.53
  13. Jiping Wang · 4 shared papers, 2020–2024 · strength 0.50
  14. Thomas Adam Abrams · 3 shared papers, 2024–2026 · strength 0.50
  15. George Molina · 3 shared papers, 2020–2026 · strength 0.50
  16. Douglas E. Biancur · 4 shared papers, 2020–2022 · strength 0.45
  17. Subhadip Mukhopadhyay · 3 shared papers, 2020–2023 · strength 0.43
  18. Keisuke Yamamoto · 4 shared papers, 2020–2021 · strength 0.42
  19. Joel Encarnación-Rosado · 3 shared papers, 2020–2023 · strength 0.41
  20. Brendan D. Parent · 2 shared papers, 2026 · strength 0.39
  21. Andressa Dias Costa · 3 shared papers, 2022–2024 · strength 0.38
  22. Michael Lawrence Dougan · 2 shared papers, 2026 · strength 0.38
  23. Courtney T.S. Kureshi · 2 shared papers, 2026 · strength 0.38
  24. Chong Zuo · 2 shared papers, 2026 · strength 0.38
  25. Hannah L. Williams · 3 shared papers, 2022–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.